SEARCH

SEARCH BY CITATION

References

  • 1
    Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112:e154e235.
  • 2
    Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001; 22:15271560.
  • 3
    Redfield MM. Heart failure—an epidemic of uncertain proportions. N Engl J Med. 2002; 347:14421444.
  • 4
    Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009; 53:e1e90.
  • 5
    Binanay C, Califf RM, Hasselblad V, et al. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. JAMA. 2005; 294:16251633.
  • 6
    Peacock WF, Costanzo MR, De Marco T, et al. ADHERE Scientific Advisory Committee and Investigators. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009; 113:1219.
  • 7
    Felker GM, O'Connor CM, Braunwald E. Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009; 2:5662.
  • 8
    Gheorghiade M, Abraham WT, Albert NM, et al. OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration, clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28:980988.
  • 9
    Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with and without congestive-heart-failure—A substudy of the studies of left-ventricular dysfunction (SOLVD). Circulation. 1990; 82:17241729.
  • 10
    Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure—activation of the neurohumoral axis. Ann Intern Med. 1985; 103:16.
  • 11
    Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008; 10:188195.
  • 12
    Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther. 1997; 62:187193.
  • 13
    Abdel-Qadir HM, Tu JV, Yun L, et al. Diuretic dose, long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J. 2010; 160:264271.
  • 14
    Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006; 97:17591764.
  • 15
    Nomura F, Kurobe N, Mori Y, et al. Multicenter prospective investigation on efficacy, safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J. 2008; 72:17771786.
  • 16
    Hata N, Seino Y, Tsutamoto T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008; 72:17871793.
  • 17
    Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006; 290:F273F278.
  • 18
    Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007; 297:13321343.
  • 19
    Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011; 25:S33S45.
  • 20
    Izumi K, Eishi K, Yamachika S, et al. The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery. Ann Thorac Cardiovasc Surg. 2008; 14:294302.
  • 21
    Carvalho VO, Bocchi EA, Guimarães GV. The Borg scale as an important tool of self-monitoring and self-regulation of exercise prescription in heart failure patients during hydrotherapy. A randomized blinded controlled trial. Circ J. 2009; 73:18711876.
  • 22
    Adams KF Jr, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee, Investigators. Characteristics, outcomes of patients hospitalized for heart failure in the United States: rationale, design, preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149:209216.
  • 23
    Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med. 2007; 167:19982005.
  • 24
    Schrier RW, Gross P, Gheorghiade M, et al. SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355:20992112.
  • 25
    Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52:15401545.
  • 26
    Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007; 49:21512159.
  • 27
    Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007; 297:13191331.
  • 28
    Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007; 297:13321343.
  • 29
    Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43:6167.
  • 30
    Cowie MR, Komajda M, Murray-Thomas T, et al. Prevalence, impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006; 27:12161222.
  • 31
    Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment, development of worsening renal function among hospitalized patients. Am Heart J. 2004; 147:331338.
  • 32
    Sato N, Kajimoto K, Asai K, et al. ATTEND Investigators. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, preliminary data. Am Heart J. 2010; 159:949955.
  • 33
    Suwa M, Seino Y, Nomachi Y, et al. Multicenter prospective investigation on efficacy, safety of carperitide for acute heart failure in the “real world” of therapy. Circ J. 2005; 69:283290.
  • 34
    Chiong JR, Kim S, Lin J, et al. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ. 2012; 15:276284.